Obesity Pharmacotherapy Advances From Stigma to WHO Recognition
A historical review traces obesity drug setbacks, stigma, and the rise of GLP-1 and multiagonist therapies to WHO guideline and listing decisions.
Trials, guidelines and clinical evidence across Endocrinology.
Trials, guidelines and clinical evidence across Endocrinology.